PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

(Thomson Reuters ONE) -


REGULATED INFORMATION


GHENT, Belgium, 6 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today
announced, in accordance with Article 14 of the Belgian Law of 2 May 2007
regarding the publication of major shareholdings in issuers whose securities are
admitted to trading on a regulated market (the "Transparency Law"), that it
received a notification of shareholdings from Bank of America Corporation on 5
July 2017.

Bank of America Corporation (taking into account the holdings of its subsidiary
undertakings) notified Ablynx that they have dropped below the 5% threshold as
of 28 June 2017 and now hold a total of 3,038,688 shares with voting rights,
representing 4.97% of the current 61,133,199 outstanding Ablynx shares (versus
5.24% notified previously).

The notified details are presented below:

+------------------------------------------------------------------------------+
| % of shares and |
| % of shares and voting rights held |
|Name of select voting rights through financial Total of both |
|subsidiaries of instruments |
|Bank of America   |
|Corporation |
| Shares Voting Shares Voting Shares Voting |
| rights rights rights |
+------------------------------------------------------------------------------+
|Merrill Lynch |
|Professional 4.96% 4.96%     4.96% 4.96% |
|Clearing Corp. |

+------------------------------------------------------------------------------+
|Merrill Lynch |
|Financial Markets,     0.01% 0.01% 0.01% 0.01% |
|Inc. |
+------------------------------------------------------------------------------+
|TOTAL 4.96% 4.96% 0.01% 0.01% 4.97% 4.97% |
|  |
+------------------------------------------------------------------------------+

Merrill Lynch Professional Clearing Corporation and Merrill Lynch Financial
Markets, Inc. are controlled by Bank of America Corporation. Bank of America
Corporation is not a controlled entity.

Full versions of all transparency notifications are available on Ablynx website,
under the section Investors.


About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
45 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple pharmaceutical
companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co.,
Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More
information can be found on www.ablynx.com.


For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  edwin.moses(at)ablynx.com

Lies Vanneste
Director Investor Relations
t:   +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e:  lies.vanneste(at)ablynx.com

Follow us on Twitter (at)AblynxABLX


Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan
t: +44 20 3727 1000
e: ablynx(at)fticonsulting.com

pdf version of the press release:
http://hugin.info/137912/R/2118249/806554.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ablynx via GlobeNewswire

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 06.07.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 551219
Anzahl Zeichen: 5250

contact information:
Town:

Ghent/Zwijnaarde

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 247 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx